STOCK TITAN
  1. Home
  2. Sec-filings
  3. GHRS
  4. [Form 3] GH Research PLC Initial Statement of Beneficial Ownership

Duncan Moore of GH Research (NASDAQ: GHRS) reports shares and vested options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

GH Research PLC director Duncan Moore filed an initial ownership report showing holdings of ordinary shares and several tranches of vested share options. He directly holds 14,600 ordinary shares and multiple option awards to acquire ordinary shares at an exercise price of 0.025 per share, with expirations ranging from 2030 to 2032. Some option grants are fully vested and exercisable, while others vest over time or within specified windows under the GH Research PLC Share Option Plan.

Positive

  • None.

Negative

  • None.
Insider Moore Duncan
Role Director
Type Security Shares Price Value
holding Share Options (Right to Buy) -- -- --
holding Share Options (Right to Buy) -- -- --
holding Share Options (Right to Buy) -- -- --
holding Share Options (Right to Buy) -- -- --
holding Share Options (Right to Buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Share Options (Right to Buy) — 6,633 shares (Direct); Ordinary Shares — 14,600 shares (Direct)
Footnotes (1)
  1. The share options are fully vested and exercisable. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of June 22, 2024. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of July 6, 2024. The share options vested as to 25% on December 9, 2025, and the remaining share options vest in equal monthly installments for three years thereafter. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of September 3, 2025.
Ordinary shares held 14,600 shares Direct holdings reported on Form 3
Option exercise price 0.025 per share Exercise price for reported share options
Option tranche underlying shares 6,633 shares Underlying ordinary shares for options expiring 2030-09-26
Option tranche underlying shares 5,508 shares Underlying ordinary shares for options expiring 2031-06-22
Option tranche underlying shares 5,532 shares Underlying ordinary shares for options expiring 2031-07-06
Largest option grant 50,000 underlying shares Options expiring 2031-12-09 with staged vesting
Later option grant 4,667 underlying shares Options expiring 2032-09-03
Share Options (Right to Buy) financial
"Security title is listed as Share Options (Right to Buy) over ordinary shares."
Ordinary Shares financial
"The options relate to underlying security titled Ordinary Shares of GH Research PLC."
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
exercise price financial
"Each option award has an exercise price of 0.025 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"Footnotes state that certain share options are fully vested and exercisable."
GH Research PLC Share Option Plan financial
"Exercise periods are subject to the rules of the GH Research PLC Share Option Plan."
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Moore Duncan
(Last)(First)(Middle)
C/O GH RESEARCH PLC
JOSHUA DAWSON HOUSE, DAWSON STREET
(Street)
DUBLINIRELANDD02 RY95
(City)(State)(Zip)
IRELAND
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
GH Research PLC [ GHRS ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares14,600D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Options (Right to Buy) (1)09/26/2030Ordinary Shares6,633$0.025D
Share Options (Right to Buy) (2)06/22/2031Ordinary Shares5,508$0.025D
Share Options (Right to Buy) (3)07/06/2031Ordinary Shares5,532$0.025D
Share Options (Right to Buy) (4)12/09/2031Ordinary Shares50,000$0.025D
Share Options (Right to Buy) (5)09/03/2032Ordinary Shares4,667$0.025D
Explanation of Responses:
1. The share options are fully vested and exercisable.
2. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of June 22, 2024.
3. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of July 6, 2024.
4. The share options vested as to 25% on December 9, 2025, and the remaining share options vest in equal monthly installments for three years thereafter.
5. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of September 3, 2025.
/s/ Duncan Moore04/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the GH Research (GHRS) Form 3 filing show for Duncan Moore?

The Form 3 shows Duncan Moore’s initial ownership in GH Research PLC, including 14,600 ordinary shares and several option grants. These options allow him to buy additional ordinary shares at a 0.025 exercise price, with expirations between 2030 and 2032.

How many GH Research (GHRS) ordinary shares does Duncan Moore hold directly?

Duncan Moore directly holds 14,600 ordinary shares of GH Research PLC as reported in the Form 3. This position is separate from his share options, which provide potential future rights to acquire additional ordinary shares at a fixed exercise price.

What are the key terms of Duncan Moore’s GH Research share options?

His options are rights to buy GH Research ordinary shares at a 0.025 exercise price per share. They have expirations from 2030 to 2032 and certain grants are fully vested and exercisable, subject to the GH Research PLC Share Option Plan rules.

Are Duncan Moore’s GH Research share options already vested?

Several option tranches are fully vested and exercisable, while one major grant vested 25% on December 9, 2025, with the remainder vesting in equal monthly installments over three years, all under the GH Research PLC Share Option Plan rules.

Do the GH Research (GHRS) Form 3 entries show any recent insider buying or selling?

No explicit buying or selling is shown; the entries are categorized as holdings with unknown transaction codes. The filing primarily lists Duncan Moore’s existing ordinary share position and his vested and vesting share option awards to acquire ordinary shares.

What expirations apply to Duncan Moore’s GH Research share options?

The share options reported have expiration dates between 2030 and 2032, including tranches expiring on September 26, 2030, June 22, 2031, July 6, 2031, December 9, 2031, and September 3, 2032, subject to the share option plan rules.